Market News for Abbvie Inc (ABBV)
AbbVie has successfully navigated through a major patent cliff, enabling it to sustain a dividend growth streak for more than a decade. Thanks to two strong product portfolios, AbbVie's underlying growth, dividend growth, and share price growth are likely to persist....
The Motley Fool - 4/7/2026 9:30:00 PM
More News for ABBV
Stock Analysis for ABBV
Related Stocks:
In the most recent trading session, AbbVie (ABBV) closed at $206.69, indicating a -1.03% shift from the previous trading day....
Zacks Investment Research - 4/6/2026 6:46:18 PM
More News for ABBV
Stock Analysis for ABBV
Related Stocks:
AbbVie remains a 'Buy,' with valuation and forward EPS growth supporting the thesis despite recent sector weakness and an 8% YTD decline. Q4 results exceeded expectations: non-GAAP EPS of $2.71 and revenue up 10% YoY, driven by Skyrizi and Rinvoq offsetting Humira declines. Management guides for FY 2026 adjusted EPS of $14.37–$14.57 and forecasts robust free cash flow ($18.5 billion), underpinning the high dividend yield....
Seeking Alpha - 4/6/2026 12:29:24 PM
More News for ABBV
Stock Analysis for ABBV
Related Stocks:
Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, revealing two very different pharmaceutical stories....
24/7 Wall Street - 4/6/2026 12:15:05 PM
More News for ABBV
Stock Analysis for ABBV
Related Stocks:
ABBV heads into Q1 earnings with Skyrizi and Rinvoq in focus as Humira declines, while growth from new indications and market share gains is under watch....
Zacks Investment Research - 4/6/2026 9:16:12 AM
More News for ABBV
Stock Analysis for ABBV
Related Stocks:
